New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
14:23 EDTNKTRNektar June volatility elevated at 127 into ASCO
Nektar June call option implied volatility is at 84, August is at 78, November is at 70; compared to its 26-week average of 70 according to Track Data, suggesting large near term price movement into ASCO's 50th annual meeting taking place May 30 through June 3.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 30, 2015
10:24 EDTNKTRBaxalta launches U.S. availability of hemophilia A treatment ADYNOVATE
Baxalta (BXLT) announced the launch and first shipments of ADYNOVATE, an extended circulating half-life recombinant factor VIII treatment for hemophilia A based on full-length ADVATE. The treatment was approved by the U.S. Food and Drug Administration in November. "Patients living with hemophilia are increasingly looking for and need treatment options that can address their individual needs," said Dr. Michael Tarantino, medical director of the Bleeding & Clotting Disorders Institute. "The simplicity of ADYNOVATE's twice weekly dosing schedule offers an important new option for the hemophilia community, delivering first and foremost on what matters most - bleed protection, while also easing the schedule of their prophylactic treatment." ADYNOVATE was developed through a collaboration with Nektar Therapeutics (NKTR).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use